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Abstract: The development of specific and age-appropriate pediatric formulations is essential to
assure that all children and their care-givers can easily access to safe and effective dosage forms. The
need for developing specific pediatric medicinal products has been highlighted by the European
Medicines Agency. The aim of this study was to investigate the effectiveness of combining the
advantages of both cyclodextrin (CD) complexation and loading into nanostructured lipid carriers
(NLC), to obtain a liquid oral pediatric formulation of hydrochlorothiazide (HCT), endowed with
safety, dosage accuracy, good stability and therapeutic efficacy. Equimolar drug combinations as
physical mixture (P.M.) or coground product (GR) with hydroxypropyl-β-cyclodextrin (HPβCD) or
sulfobutylether-β-cyclodextrin (SBEβCD) were loaded into NLC, then characterized for particle size,
homogeneity, Zeta potential, entrapment efficiency, gastric and storage stability. The presence of
HPβCD allowed higher entrapment efficacy than NLC loaded with the plain drug, and enabled,
in the case of GR systems a complete and sustained drug release, attributable to the wetting
and solubilising properties of HPβCD toward HCT. In vivo studies on rats proved the superior
therapeutic effectiveness of HCT-in HPβCD-in NLC formulations compared to the corresponding free
HCT-loaded NLC, thus confirming the successfulness of the proposed approach in the development
of an efficacious liquid oral formulation of the drug.
Keywords: hydrochlorothiazide; drug-in cyclodextrin-in nanostructured lipid carriers; oral liquid
formulations for children; gastric stability; storage stability; in vivo diuretic effect
1. Introduction
The development of specific and appropriate pediatric formulations is essential to assure that all
children, of different ages, as well as their care-givers, can easily access to safe and accurate dosage
forms. The European Medicinal Agency recently pointed out the need for developing medicinal
products appositely designed for use in pediatric population, by providing specific guidelines with
harmonized recommendations on the different aspects to be taken into account [1]. In fact, the lack
of an adequate availability of medicines appositely developed for pediatric use resulted in the last
decades in several off-label and unlicensed prescriptions, increasing the risks of adverse drug reactions,
which may be more severe or different from those in adults [2]. Moreover, this problem also had as a
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consequence a wide use of extemporaneous preparations, obtained, starting from formulations for
adult people, by dilution of liquid dosage forms or by tablet crushing or capsule opening, leading
to administration of drugs with poor/uncontrolled dosing accuracy, unknown stability, variable
bioavailability, poor compliance for children and care-givers [3]. Furthermore, the excipients of tablets
or capsules for adults could be potentially toxic or unsuitable for pediatric patients [4]. The obtainment
of a well homogeneous distribution of the drug is an additional issue to be taken into account, due to
its very low dosage.
Diuretic drugs are often used in hypertension treatment of pediatric patients and, among these,
hydrochlorothiazide (HCT) is included in the WHO Model List of Essential Medicines for children [5].
Extemporaneous liquid pediatric formulations of HCT are generally prepared in hospital pharmacies
by dispersion of the drug powder in a sugar solution [6] or by suspension in a liquid vehicle of a
ground fraction of a commercial tablet [7], with all the drawbacks above described [3]. In addition, it
must be considered that HCT, a class IV drug according to the Biopharmaceutic Classification System
(BCS) [8], presents problems of limited and variable bioavailability, related to its low solubility and
permeability [9,10]. Moreover, the poor solubility and limited stability of HCT in aqueous solution [11],
make the development of stable aqueous liquid formulations of the drug very difficult [12,13]. In fact,
at present, there are not liquid formulations of HCT available on the market, while they should be
very useful, particularly in the pediatric field.
The use of liquid lipid-based nanocarriers is a promising and versatile approach for delivery of
hydrophobic drugs, due to their safety, biocompatibility and biodegradability, and their ability to improve
dissolution and permeation properties of drugs, thus enhancing their oral bioavailability [14,15]. Among
these, solid lipid nanoparticles (SLN), a colloidal carrier class composed by solid, physiologically
compatible lipids dispersed in an aqueous surfactant phase, represent an interesting alternative to
other colloidal systems such as liposomes or microemulsions; in fact, they offer analogous benefits,
but allow to overcome their principal drawbacks, such as the limited entrapment efficiency and poor
stability [16,17]. Moreover, the presence of the solid lipid matrix provides further advantages, including
the protection of the embedded drug and the possibility of obtaining a controlled release [18–20]. A
HCT-in SLN oral pediatric formulation has been recently successfully developed, endowed with
satisfying entrapment efficiency (around 57%) and 1 month stability at 4 ◦C [21]. Nanostructured lipid
carriers (NLC) have been recently proposed as an improved generation of lipid nanoparticle, with the
aim of overcoming some potential drawbacks shown by SLN, such as in particular the tendency to expel
the drug during storage as a consequence of their highly ordered crystalline structure [22,23]. NLC are
composed by a solid lipid matrix, consisting of a mixture of biocompatible solid and liquid lipids, and
an aqueous phase containing a surfactant or a blends of surfactants. The presence of the liquid lipids
leads to a special nanostructure, with a less-ordered crystal lattice and increased imperfections in the
solid matrix core, thus allowing to maintain the advantages of SLNs as drug carriers, while offering
some additional important benefits such as facilitated incorporation of higher drug amounts, enhanced
physical stability, lower drug leaking during storage [24,25]. Recently, NLC have been investigated to
improve the oral bioavailability of different poorly water-soluble drugs [26,27].
A HCT-in NLC oral pediatric formulation has been recently successfully developed [28], which
exhibited improved drug entrapment efficiency and higher stability under storage with respect to the
corresponding previous SLN formulation [21].
Cyclodextrin (CD) complexation has been widely and successfully used to enhance solubility,
dissolution rate and thus the bioavailability of several poorly soluble drugs [29] including HCT [30,31].
The effectiveness of simultaneously exploiting the advantages of both CD and nano-lipid carriers
by joining them in a unique drug delivery system, by loading the drug-CD system into the lipid
nanoparticles, has recently been reported [32–35]. In particular, loading into SLN of HCT as HPβCD
binary system rather than as plain drug allowed to enhance the entrapment efficiency from 57% up to
66%, to prolong the formulation stability at 4 ◦C from 1 to 3 months, and to improve the drug release,
with an almost 3-times increase of the released amount after 6 h [21].
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Therefore, based on all these considerations, we deemed it worthy of interest to investigate the
usefulness of a combined strategy based on loading HCT as CD system into NLCs formulations, to
obtain a stable and effective liquid formulation of HCT suitable for the oral pediatric therapy. With
this purpose, the effect of HCT complexation with two different β-CD derivatives was considered,
i.e., hydroxypropyl-β-CD and sulfobutylether-β-CD selected due to their absence of toxicity, being
the only two β-CD derivatives admitted for parenteral use [36] and present in the FDA’s list of
Inactive Pharmaceutical Ingredients. The effect of CDs was investigated in terms of particle size and
homogeneity, Zeta-potential, entrapment efficiency, gastric and storage stabilities and drug release
properties of NLCs, compared to the previously developed NLC formulations containing the plain
drug. Finally, the best HCT-CD-loaded NLC formulation was chosen for performing in vivo studies on
rats, in order to evaluate its actual effectiveness in enhancing diuresis with respect to the corresponding
formulation loaded with the plain drug and to a simple drug aqueous suspension.
2. Materials and Methods
2.1. Materials
Hydrochlorothiazide (HCT) was kindly supplied by Menarini (L’Aquila, Italy).
Hydroxypropyl-β-cyclodextrin (Kleptose®HP, HPβCD average substitution degree DS = 0.85)
and β-cyclodextrin were a gift from Roquette (Lestrem, France) and Sulfobutylether-β-cyclodextrin
(Captisol®, SBEβCD) from Ligand Pharmaceuticals, Inc. (San Diego, CA, USA). Precirol®ATO5
(Glyceryldistearate NF/glycerylpalmitostearate), was kindly provided by Gattefossé (Milan, Italy);
polyoxyethylene (Tween®80) was from Merck (Hohenbrunn, Germany), Poloxamer 188 (Pluronic®F68)
from BASF (Ludwigshafen, Germany) and castor oil from Galeno (Prato, Italy). Purified water was
obtained by reverse osmosis (Elix® Millipore, Baltimore, MD, USA). All other chemicals were of
analytical grade.
2.2. Phase-Solubility Studies
Phase-solubility studies were performed at 25 ◦C adding an excess amount of drug (50 mg)
in 10 mL of pH 5.5 phosphate buffer solutions, containing increasing concentrations of HPβCD or
SBEβCD (0–25 mM) put in sealed glass containers, preserved from the light and electromagnetically
stirred (500 rpm) [37]. Aliquots were withdrawn every 24 h with a filter syringe (0.45 µm pore size)
until equilibrium (72 h), and spectrometrically assayed for drug content at 272.2 nm (UV–vis 1600
Shimadzu spectrophotometer, Tokyo, Japan). Each test was carried out in triplicate (coefficient of
variation, C.V. < 4%). The apparent stability constant (K1:1) and the complexation efficiency (CE) of the
complexes were estimated using the following equations:
K1:1 =
slope
S0(1− slope) (1)
CE =
slope
1− slope (2)
where the slope is calculated from of the straight line portions of the phase-solubility diagrams and S0
is the drug solubility in the absence of CD.
2.3. Preparation of Drug-CD Binary Systems
Physical mixtures (P.M.) of HCT with HPβCD and SBEβCD at 1:1 drug to carrier molar ratio were
obtained by simple blending the powders for 15 min in a turbula mixer. Coground products, (GR)
were instead obtained by grinding physical mixtures in a high-energy vibrational micromill (Mixer
Mill Type MM 200, Retsch, GmbH, Düsseldorf, Germany) at 24 Hz for 30 min according to a previously
developed method [21]. HCT was submitted to the same process for comparison purpose.
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2.4. Dissolution Rate Studies
Dissolution studies were carried out according to the dispersed amount method. A sample of
200 mg of drug (untreated or submitted to grinding) or drug-equivalent, previously sieved (75–150 µm
granulometric fraction), was added to 75 mL of pH 5.5 phosphate buffer solution thermostated at 37 ±
0.5 ◦C, in a 150 mL beaker. A three-blade paddle (1.5 cm radius) was centrally put in the beaker and
rotated at 100 rpm. Aliquots (3 mL) periodically withdrawn with a syringe-filter (pore size 0.45 µm)
were spectrometrically assayed for drug content as described above, and replaced with an equal
volume of fresh medium. A correction for the cumulative dilution was made. The results are the mean
of four experiments.
2.5. Preparation and Characterization of NLC
NLC were prepared by the hot high-shear homogenization technique followed by
ultrasonication [21].The aqueous phase, containing a nonionic hydrophilic surfactant (Pluronic®F68
or Tween®80, 1.5% w/w), was heated up to 65 ◦C (i.e., 10 ◦C above the melting point of the lipid
mixture) and dispersed in the molten lipid phase (Precirol®ATO5) added of the liquid lipid (castor
oil) by 2 min stirring at 10,000 rpm with a T25 digital ULTRA-TURRAX® homogenizer (IKA®Werke,
Staufen, Germany). The obtained pre-emulsion was then sonicated for 3 min by a Sonopuls HD 2200
sonicator (Bandelin Electronics, Berlin, Germany) and finally cooled at 4 ◦C to solidify the lipid matrix
and produce NLC.
Drug-loaded NLC were prepared by incorporating HCT as such (200 mg) in the lipid phase or
by adding the selected HCT-CDsystem (as P.M. or GR, equivalent to 200 mg HCT) to the aqueous
surfactant solution, respectively. The final drug concentration was 0.2% w/v.
All samples were protected from light and stored at a temperature of 4 ◦C.
2.6. Physicochemical Characterization of NLC
Particle size, Polydispersity Index (PDI) and Zeta-potential of the different HCT-loaded NLC
formulations were determined by dynamic light scattering (DLS) using a Zetasizer Nano-ZS90
(Malvern Instruments Ltd., Worcestershire, UK) after appropriate dilution with purified water in
order to prevent possible multiscattering phenomena.
Entrapment Efficiency (EE%) and loading capacity (LC%) of HCT-loaded NLC were determined
indirectly, by determining the concentration of free drug present in the aqueous phase after
ultrafiltration of the colloidal dispersion using a membrane concentrator (Vivaspin®2, 10,000 kDa
MWCO, Sartorius Stedim Biotech Ltd., Göttingen, Germany). An aliquot (1.5 mL) of HCT-loaded
NLC aqueous dispersion was placed in the upper chamber and centrifuged 8 min at 4000 rpm
(HERMLE Labortechnik, mod. Z200A, Wehingen, Germany). The un-encapsulated drug, collected in
the filtrate recovered in the lower chamber, was spectrophotometrically assayed at 272.2 nm (UV-1601
spectrophotometer, Shimadzu Corporation, Kyoto, Japan). No interferences by lipids and other
components were detected in the spectrophotometric determination of the drug.
The following Equations (3) and (4) were used to calculate entrapment efficiency (EE%) and
loading capacity (LC%), respectively:
EE% =
Winitial drug −Wfree drug
Winitial drug
× 100 (3)
LC% =
Winitial drug −Wfree drug
Wlipid
× 100 (4)
where Winitial drug is the total amount of drug initially added, Wfree drug is the amount of
un-encapsulated drug and Wlipid is the weight of the total lipids used.
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For each sample five separate experiments were carried out and the results are reported as the
mean values ± S.D.
2.7. Stability Studies Under Gastric Conditions
The intra-gastric stability of empty NLC and NLC loaded with HCT alone or in combination with
CD was evaluated in a simulated gastric solution (pH 4.5 phosphate buffer, miming the infant gastric
pH [38]. Samples of 1 mL of each dispersion were suspended in 100 mL of simulated gastric solution
thermostated at 37 ◦C. Size and PDI of NLC dispersions were measured immediately (t0) and after
2 h incubation (t2 h). Experiments were performed in triplicate and the results represent the average
values ± S.D.
2.8. Storage Stability Studies
NLC formulations were stored at 4 ◦C for three months. At given time intervals (1 month), the
mean particle size, PDI and Zeta Potential were determined in triplicate and the results were averaged.
Possible phenomena of crystallization, formation of precipitates, gelling and/or growth of moulds
were also checked by visual inspection.
2.9. Drug Release Studies
In vitro HCT release experiments from NLC formulations were carried out in sink conditions, by
the dialysis bag method [32].The results were compared to those obtained from 0.2% w/v aqueous
suspensions of the drug, alone or as equimolar P.M. or GR system with CD. 1 mL sample of NLC
dispersion or drug aqueous suspension (all containing 2 mg of drug) was put into a cellulose acetate
dialysis bag (Sigma-Aldrich, St. Louis, MO, USA, 12,500 cut-off) previously soaked overnight in pH
4.5 phosphate buffer (miming the infant gastric pH) and sealed with a clamp at both sides to prevent
leakage. The bag was placed 2 h in 100 mL of pH 4.5 gastric buffer (HCT solubility in the medium
about 0.7 mg/mL) and then 4 h in 100 mL of pH 6.8 phosphate buffer (simulating the intestinal pH),
both thermostated at 37 ◦C and stirred at 50 rpm.
The HCT released amount was spectrometrically assayed at 272.2 nm at predetermined times.
After sampling of the receiver solution, an equal volume of fresh solvent was replaced, to keep the
volume constant. A correction for the cumulative dilution was made. Experiments were carried out in
triplicate and the results are expressed as the mean values ± S.D.
2.10. In Vivo Studies
Male Sprague-Dawley rats (Harlan, Varese, Italy) weighing around 200–250 g at the start of the
procedure, were used for all the in vivo studies. The rats, housed in CeSAL (Centro Stabulazione
Animali da Laboratorio, University of Florence, Italy), were used not before a week by their arrival.
Animals, housed in suitable cages (4 for cage of 26 × 41 cm), were acclimatized at a temperature of 23
± 1 ◦C, subjected to a 12 h light/dark cycle, (with light at 7 a.m.), and fed with a standard laboratory
diet and tap water ad libitum. All manipulations of animals were performed in agreement with the
Directive 2010/63/EU of the European Parliament and of the European Union Council (09/02/2010)
on the protection of animals used for scientific aim. The ethical policy of Florence University complies
with the Guide for Care and Use of Laboratory Animals of US National Institutes of Health (NIH
Publication No. 85–23, revised 1996; University of Florence assurance number: A5278-01). Formal
approval to carry out the experiments (project 108678, 28/06/2017) was given by the Animal Subjects
Review Board of the University of Florence. Experiments involving animals have been carried out in
compliance with ARRIVE guidelines [39]. Every effort has been made to minimize animal suffering
and restrict the number of animals to use.
The diuretic activity was determined following the method of Compaore et al. [40] with some
variations. Animals were randomly divided into five groups (n = 5) for the acute (single dose) study
with free access to food and water. Before each treatment, the rats received an oral dose of 2.5 mL/100
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g body weight of physiological saline (0.9% NaCl) to impose a uniform water and salt load [41]. One
hour later, a dose of 10 mg kg−1 was orally administered to the rats in the following manner: control
group, with 0.9% saline; group I with empty NLC; group II with HCT aqueous suspension (0.2% p/v
HCT); groups III and IV with the selected NLC formulation loaded, respectively, with the drug alone
or as GR with HPβCD. Immediately after administration, the rats were put in suitable metabolic cages
(one rat per cage), specifically designed to separate urine from feces. The cumulative urine output at 1,
2, 4, 6 and 24 h was determined. The diuretic activity was expressed as mL/100 g of body weight [42].
The diuretic index was obtained by the ratio of the diuresis of rats treated with the test formulation
and that of the control group [43]. AUC0–6 h and AUC0–24 h (area under the urine volume curve versus
time) were calculated according to equation (5):
AUC =
1
2
(V1 + V2)(t2 − t1). (5)
where V is the volume of urine (mL) recovered at the time t(h).
2.11. Statistical Analysis
One-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls multiple
comparison post test was employed to statistically analyse the results of all in vitro experiments
(Graph Pad Prism version 6.0 software, San Diego, CA, USA). The results of in vivo studies were
treated by one-way analysis of variance, applying a Bonferroni’s significant difference procedure
as a post hoc comparison (Origin 9 software, OriginLab, Northampton, MA, USA). In all cases, the
differences were deemed statistically significant when P < 0.05 or <0.01.
3. Results and discussion
3.1. Phase Solubility Studies
Phase-solubility studies evidenced the solubilizing and complexing properties of the examined
CDs towards HCT. AL type phase-solubility diagrams were obtained with both CDs, characterized by
a linearincrease of drug solubility with increasing CD concentration, as a consequence of the formation
of soluble complexes [37] (see the Supplement, Figure S1). The 1:1 apparent stability constants (K1:1)
of HCT-HPβCD and HCT-SBEβCD complexes were 106 and 210 M−1, respectively and the calculated
complexation efficiency (CE) values were 0.220 and 0.436, respectively.
3.2. Dissolution Studies
Dissolution studies were performed on the drug alone, untreated or submitted to grinding
procedure and on the drug CD P.M. and GR systems. As showed in Figure 1, ground HCT showed
an initial faster dissolution rate than the untreated drug, due to the particle reduction induced by
the treatment. The P.M. obtained with both CDs showed a more evident increase in drug dissolution
rate, attributable to the wetting and solubilising effect of the CDs; this effect became even more
marked for GR products, in virtue of the better interaction established between drug and CD
by the co-grinding treatment. Previous solid state studies performed by DSC and X-ray powder
diffractometry showed total drug amorphization and/or complexation in its GR products with HPβCD
and HCT-SBEβCD [21].According to the results of phase solubility studies, SBEβCD demonstrated
higher solubilising power towards HCT with respect to HPβCD.
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3.3. Preparation and Characterization of Drug-Loaded NLC
In a previous study, we successfully developed a liquid pediatric oral NLC formulation of
HCT [28], which showed better properties in terms of stability and entrapment efficiency than the
previously developed SLN formulation of the same drug [21].
Therefore, as a continuation of this study, in the present work we investigated the possibility
of further improving the effectiveness of HCT as NLC formulation, by loading the drug as CD
system, considering the positive results obtained by such a combined approach in the case of SLN
formulations [21]. With this aim, new series of NLC formulations composed by Precirol®ATO5
and castor oil (90:10 w/w ratio) as solid and liquid lipid, respectively, were prepared. Tween®80
or Pluronic®F68 (1.5% w/w) were used as surfactantssince previously selected as the most suitable
ones [21,28]. The formulations were loaded with the drug as such (reference formulation) or in
combination (in a 1:1 molar ratio) with selected CDs (HP®CDor SBEβCD), as simple physical mixture
(P.M.) or as coground product (GR) [21]. To be able to evaluate the effect of the CD presence on NLC
formulations compared to that previously observed for the corresponding SLN formulations, the
same hot high-share homogenization method followed by ultrasonication was used for nanoparticle
preparation.NLC formulations were characterized in terms of mean particle size, Polydispersity Index,
Zeta-potential, Encapsulation Efficiency and Loading Capacity (see Table 1).
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Table 1. Composition of the different NLC formulations, all containing Precirol®ATO5 as solid lipid
and castor oil as liquid lipid (90:10 w/w ratio) and their properties in terms of mean size, polydispersity
index (PDI), Zeta potential (ζ), Encapsulation Efficiency (EE%) and Loading Capacity (LC%).
Formulation
code
Surfactant type
(1.5%w/w) Drug-CD system * Size (nm) PDI ζ (mV) EE% LC%
NLC1 Tween®80 HCT alone 563.3±3.7 0.36±0.03 −31.6±1.6 80.0±0.2 3.2±0.01
NLC3 Tween®80 HCT-HPβCD P.M. 539.8±10.9 0.32±0.09 −30.1±0.6 88.8±0.1 3.5±0.01
NLC5 Tween®80 HCT-HPβCD GR 550.1±15.1 0.32±0.03 −34.4±1.0 87.7±0.1 3.5±0.01
NLC7 Tween®80 HCT-SBEβCD P.M. >1000 - - - -
NLC9 Tween®80 HCT-SBEβCD GR >1000 - - - -
NLC2 Pluronic®F68 HCT alone 405.4±3.8 0.22±0.02 −38.8±1.4 40.1±3.2 1.6±0.13
NLC4 Pluronic®F68 HCT-HPβCD P.M. 395.6±3.7 0.28±0.08 −34.0±1.1 68.7±1.3 2.7±0.05
NLC6 Pluronic®F68 HCT-HPβCD GR 403.8±3.8 0.25±0.03 −34.3±0.7 68.2±0.5 2.7±0.02
NLC8 Pluronic®F68 HCT-SBEβCD P.M. >1000 - - - -
NLC10 Pluronic®F68 HCT-SBEβCD GR >1000 - - - -
* all equivalent to 200 mg HCT.
As previously observed in the case of SLN dispersions [21] and in accordance with the findings of
other authors [44,45], Tween®80 gave rise to nanoparticle of larger size than Pluronic®F68, probably
as a consequence of its different affinity for lipids that give rise to differences in incorporation of the
surfactant in the outer shell of the particles [46]. In fact, Tween®80 due its lower HLB (Hydrophilic
lipophilic balance) with respect to Pluronic®F68 (15 vs. 29 as reported in the technical sheets) can
better interact with the lipid components of NLC, giving rise to a larger thickness of the coating layer
on the particle surface and, consequently a greater particle size.
Loading of the drug in combination with HPβCD did not negatively influence NLC formation,
whose mean particle size resulted only slightly lower with respect to that of the corresponding NLC
formulations loaded with the free drug, regardless the type of surfactant used. The low PDI values,
similar to those of free HCT-loaded NLC, suggested the obtainment of uniformly nano-dispersed
colloidal systems. Negative Zeta potential values, all higher than 30 mV, were obtained, almost
unchanged with respect to free HCT-loaded NLC. No important differences were observed when
adding the drug as P.M. or as GR product with HPβCD. All these results indicated that the presence of
HPβCD itself did not affect the physicochemical properties and stability of NLC dispersions.
On the contrary, the addition of HCT in combination with SBEβCD, in the presence of both
Pluronic®F68 or Tween®80 as surfactant, produced particles of large and not homogeneous dimensions,
greater than 1000 nm and with PDI values higher than 1. Such a finding, analogous to that previously
observed in the case of SLN dispersions [21] has been attributed to a possible interaction between the
anionic SBEβCD and the surfactants present in both SLN and NLC formulations, leading to a variation
in their solubilising capacity, thus modifying the water uptake by the lipid phase and, consequently,
adversely affecting the particle formation and their stability [47].
Loading of HCT as equimolar system with HPβCD resulted in an increase of EE% with respect
to NLC loaded with the plain drug, ranging from 11% in the presence of Tween®80 up to 70% in the
presence of Pluronic®F68. Also in this case, no appreciable variations where detected when adding
the drug-HPβCD system as simple P.M. or as GR product. Comparable positive effects on EE% of
drug loading in combination with a suitable CD have been reported in case of SLN loaded with
hydrocortisone as βCD complex [48] and of NLC loaded with ketoprofen as complex with polymeric
βCD [32] obtaining an EE% increase of 70 and 77%, respectively, compared to the corresponding
formulations loaded with the plain drug. A similar finding was also observed for SLN formulations
of HCT in the presence of HPβCD [21]. Moreover, the EE% of the presently developed “drug-in
HPβCD-in NLC” system was clearly higher than that of the previous “drug-in HPβCD-in SLN”.
In fact, the best NLC formulation reached an EE% value nearly 89% vs. the 66.5% value obtained
with the best SLN [21]. Analogous results were found for LC% values. The better drug loading ability
of NLC with respect to the corresponding SLN formulations can be attributed to the formation of
imperfections in the crystal lattice of the solid lipid (Precirol®ATO), due to the incorporation of the
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liquid lipid (castor oil), thus leading to a less ordered structure, able to accommodate larger drug
amounts [49–51].
3.4. Stability Studies of NLC Formulations in Gastric Conditions
The gastrointestinal stability of lipid formulations plays a crucial role to assure a controlled and
reproducible drug release profile during their transit. In particular, the acidic medium may destabilize
lipid carriers, thus leading to aggregation phenomena and, consequently, negatively influencing the
drug release properties. The gastric stability of NLC dispersions was evaluated by determining any
variation in the mean size and PDI of the particles after incubation at 37 ◦C for 2 h in pH 4.5 buffer
solution, chosen as an average pH value for infant population [38].The addition of proteolytic enzymes,
such as pepsin or trypsin, was not judged necessary, considering the lipid nature of the formulations
under study. On the other hand, the use of a lipolysis model was not possible, since the differences
between adults and pediatric population make the adaptability of the various in vitro models designed
for adults unsuitable for miming pediatric conditions. In addition, it has to be considered the lack
of commercial availability of Human Gastric Lipase (HGL) and Pancreatic Lipase-Related Protein 2
(PLRP2), reported as the most active lipolytic enzymes in neonates [52–54], as well as the difficulty of
determining their levels [55].
Figure 2 reports the gastric stability of the developed NLC formulations in terms of mean
dimensions (A) and PDI (B).
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The particle size of the Tween®80-based NLC (odd series) did not considerably change after 2h
exposition, as prev ously observ d for the corresponding SLN [21].
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On the contrary, in the case of Pluronic®F68-based NLC (even series) a growth in the particle size
was observed immediately after exposition to the gastric medium, and a further growth was found at
the end of the test (2 h), indicative of strong aggregation phenomena induced by the low pH of the
gastric medium.
The different behaviour of NLC containing Pluronic®F68 with respect to the corresponding
ones containing Tween®80, could be attributed to the different HLB values of the two surfactants
that, having a different affinity for the lipids of NLC, as well for the gastric medium, give rise to a
different stabilizing effect, as also observed by different authors [46,56–58]. Moreover, in the case of
Tween®80-based NLC, an additional stabilizing effect was provided by HPβCD, probably attributable
to interactions between Tween®80 and CDs enabling a synergistic interfacial tension decrease and
viscosity increase of the dispersed system [59].
On the contrary, a concomitant destabilizing effect was revealed by Pluronic®F68-based NLC in
the presence of HPβCD. It could be attributed to a possible interaction between the hydroxyl groups of
HPβCD and the polypropylene oxide (PPO) blocks of Pluronic, leading to supramolecular structures,
as reported by several authors [60–62]. Such an interaction, promoted by the low gastric pH, could
lead to a decrease in the Pluronic®F68 surfactant function and, consequently, to a deconstrution of the
lipid dispersions in the gastric environment.
An analogous finding was previously observed for Pluronic®F68-based SLN formulations
containing HPβCD [21].The low PDI values of NLC remained almost unchanged, thus indicating the
maintenance of a homogeneous dimensional distribution for all the colloidal dispersions (Figure 2B).
3.5. Release Studies from NLC
Based on the results of gastric stability studies, Pluronic®F68-based NLC were then discarded,
whereas the series of Tween®80-based NLC was selected for in vitro release studies. The release
profiles of these formulations loaded with the drug as such or as P.M. or GR system with HPβCD are
depicted in Figure 3, together with that of HCT-HPβCD GR or HCT aqueous suspension as reference,
all at the same drug concentration (0.2% w/v).
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Figure 3. In vitro Hydrochlorothiazide (HCT) release profiles from Tween®80-based NLC containing
the drug as such (NLC1) or as P.M. (NLC3) or GR system with HPβCd (NLC5), from its suspensions
containing the drug as such or as P.M. or GR systems with HPβCD, all at the same drug concentration
(0.2% w/v).
The drug suspension exhibited an initial rather fast release rate, in virtue of the rapid diffusion of
the drug fraction already present in solution; however, a plateau phase was rapidly achieved, slightly
exceeding 40% released drug. A better drug release rate was observed for the NLC formulation loaded
with the plain HCT (NLC1), which reached almost 60% released drug. Similarly, a greater drug release
rate from its NLC formulation than from its suspension was observed also in the case of tacrolimus [63].
As expected, a faster drug release was obtained for P.M. and GR systems with HPβCD, which both
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reached the maximum released % (around 60%) after only 30 min. However, the total amount of
released drug, even if higher than that of drug alone (around 40%) was incomplete, and similar to that
obtained from NLC loaded with the plain drug (60% released after 6 h). On the contrary, significantly
better release profiles were obtained from NLC containing HCT as P.M. (NLC3) (80% released after
6 h) and even more as GR (NLC5) (100% released after 6 h) with HPβCD. Such an improvement
could be ascribed to the high wetting ability and solubilizing properties of HPβCD toward the drug
combined with the effect of the nanocarrier. The initial fast release rate observed from all the NLC
formulations could be attributed to the quick diffusion of unentrapped HCT. The better performance of
NLC loaded with the coground product with respect to the simple physical mixture can be attributed
to the more intense drug-CD interactions obtained in such system by the preparation method, and then
to a more effective solubilizing effect. An analogous result was previously observed in the case of NLC
dispersions loaded with ketoprofen as P.M. or GR product with a polymeric βCD derivative [32].A
similar trend in the drug release rate (drug-in CD-in NLC > drug in NLC > drug suspension) has been
reported in the case of vinpocetine [33].
3.6. In Vivo Studies
The diuretic effect of theTween®80-based NLC formulation loaded with the drug as GR product
with HPβCD, elected as the best formulation based on the results of in vitro release studies, was
evaluated in rats, in comparison with that of the corresponding empty NLC, NLC formulation loaded
with the plain drug and a simple drug aqueous suspension, all orally administered at the same dose
(10 mg/Kg). The induced diuretic effect was measured as total volume of excreted urine, diuretic
activity (volume of excreted urine per 100 g body weight), and diuretic index, with respect to a control
group treated with saline (Figure 4).
Empty NLC showed similar values (P >> 0.05) to those obtained from the control in terms of
both volume of excreted urine and diuretic activity, allowing to rule out any possible effect on diuresis
exerted by the components of the nanoparticles.
Administration of the drug aqueous suspension produced a significant increase (P < 0.05) of the
diuresis at 1 h after the treatment with respect to the control group, which was maintained up to 6h.
Treatment with the drug as NLC dispersion showed a urinary output comparable to that induced
by HCT suspension. An appreciable increase in the excreted urine volume and diuretic activity was
instead observed in the case of administration of NLC dispersion loaded with the drug as coground
product with HPβCD, which gave rise to higher values than those of both HCT suspension and plain
HCT in NLC just after 2 and 4 h and displayed significantly (P < 0.01) superior effects starting from
6 h after treatment, which were maintained up to 24 h (Figure 4A,B). Similar results were observed
also for the diuretic index (Figure 4C), confirming the superior therapeutic effectiveness of the HCT-in
HPβCD-in NLC formulation with respect to the corresponding formulation loaded with the free
drug. In virtue of the absence of diuretic effect shown by empty NLC, we can state that the combined
approach of CD presence and entrapment into nanoparticles actually allowed an improved drug
bioavailability leading to a superior therapeutic activity.
To better evidence the overall effect of the different treatments, the AUC0–6 h and AUC0–24 h (area
under the urine volume curve versus time) were determined. The data confirmed the improved
bioavailability of HCT when administered as HPβCD complex loaded in NLC: in fact, the AUC0–6 h
and AUC0–24 h values of such formulation were, respectively, about 25 and 40% higher than those of
both the corresponding NLC formulations containing the plain drug and the drug suspension.
The better performance of the HCT-in HPβCD-in NLC formulation with respect to the
corresponding NLC formulation loaded with plain HCT could be attributed to several factors,
including the higher drug entrapment efficiency and, in particular, the better drug release profile;
moreover, a possible permeation enhancer effect due to the CD presence could also be hypothesized.
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An improved bioavailability of NLC loaded with the drug as CD complex with respect to those
containing the free drug has been reported in the case of Vinpocetine, and attributed to a solubilizing
effect and a faster release rate of the drug from the lipid matrix, in virtue of the drug complexation [33].
On the other hand, a comparison with the in vivo performance of the corresponding HCT-in
HPβCD-in SLN formulation was not possible, since it was discarded for in vivo studies; in fact, its
too fast release rate shown by in vitro studies was considered unsuitable for obtaining the desired
controlled release profile [21].Pharmaceutics 2018, 10, x FOR PEER REVIEW  12 of 17 
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(B) and diuretic index (C) after oral administration (10 mg kg−1) of Hydrochlorothiazide (HCT) as
aqueous suspension or as GR product with HPβCD loaded into Tween®80-based NLC, compared to
control group treated with a same volume of physiological saline (0.9% NaCl). * P < 0.05 and ** P < 0.01
vs. control group; ˆˆ P < 0.01 vs. HCT suspension; ++ P < 0.01 vs. HCT-loaded NLC.
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3.7. Stability Studies on Storage
NLC formulations were stored at 4 ◦C over 3 months and checked for mean dimensions,
polydispersity index (PDI) and Zeta potential (Figure 5A–C). These experimental conditions were
selected according to those used in the case of the previously developed NLC formulations loaded
with the plain drug [21], in order to be able to compare the obtained results.
A moderate reduction of particle size was registered over the storage time, as previously observed
in the case of SLN formulations [21]. It could be a consequence of some minor loss of lipids occurring
in the presence of partially esterified glycerides such as Precirol®ATO5 [45,46]. NLC loaded with the
pure drug were considered stable only up to 2 months, since the progressively marked increase in the
PDI occurring over this time could indicate a very polydisperse system (Figure 5B). However, such
formulation was more stable than the corresponding SLN, thus confirming the actual advantages of
using NLC rather than SLN. On the contrary, no important variations of PDI values were observed
for NLC3 and NLC5 containing the drug as CD system during all the examined period, indicating
the existing of monodisperse homogeneous systems even after three months. Zeta potential kept
negative values greater than −25mV during the whole storage time (Figure 5C), thus confirming
the physicochemical stability of such formulations and the positive influence of the presence of the
cyclodextrin, as previously observed [21].
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4. Conclusions
In this study, the usefulness of a combined strategy, based on the drug interaction with a suitable
CD, and the loading of the binary systems into NLC, has been evaluated in the development of an
oral liquid formulation of HCT intended for pediatric use, able to assure safety, dosage accuracy,
stability and therapeutic efficacy.Thus, the grinding procedure confirmed its efficiency for preparing
cyclodextrin inclusion complex in the solid state [64].
Among the CDs initially examined as complexing agents for the drug, SBEβCDwas rejected,
since its presence did not enable the formation of NLC of suitable nanometric dimensions. Instead,
the addition of the HCT-HPβCDcombination, both as simple P.M. or as GR product, allowed the
obtainment of homogeneous NLC dispersions, with mean particle size, PDI and Zeta potential values
substantially similar to those of the corresponding NLC formulations loaded with the plain drug, but
withsignificantlyincreased entrapment efficiency.
Moreover, the presence of HPβCD, in virtue of its solubilizing and wetting properties, enabled
to enhance the HCT release rate from NLC formulations with respect to those containing the plain
drug. A more marked effect was foundin the case of NLC loaded with the HCT-HPβCDGR product,
where a synergistic effect of two carriers allowed the obtainment of a complete and controlled drug
release. In addition, the presence of CD positively influenced the stability of such formulations, due to
its preservative effect.
Such last NLC formulation, selected for in vivo studies on rats, showed a significantly (P < 0.01)
more intense and prolonged diuretic effect not only than a simple HCT aqueous suspension, taken as
reference, but also than the corresponding NLC formulation loaded with the plain drug, definitely
proving the actual successfulness of the proposed HCT-in HPβCD-in NLC formulative approach.
Further studies are ongoing, in order to investigate the possibility of extending the shelf-life of
the developed formulation by freeze-drying the NLC dispersion and reconstitution at the time of use.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/10/4/287/s1,
Figure S1: Phase solubility studies of HCT with SBEβCD () and with HPβCD ().
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